A study published in JAMA Network Open found that glipizide, a common diabetes drug, may increase heart failure and death risk by 13% compared to newer DPP-4 inhibitors. Researchers urge individual evaluation of sulfonylureas and call for more research to understand glipizide's cardiovascular effects in type 2 diabetes patients.